SMS Pharmaceuticals reports robust Q2FY24 operational performance
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
The plant has a capacity for extraction of 2500 mt of poppy straw and 300 mt poppy gum per year
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The delegation's visit covered a wide range of topics
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
The medical device sector is considered as one of the sunrise sectors in the country
Subscribe To Our Newsletter & Stay Updated